What Daily Jang reports about Ozempic weight loss
Pakistan’s Daily Jang has described substantial weight loss and common digestive side effects among Ozempic users in its account of treatment in 2026. Its report puts weight loss at 10–15 per cent over several months alongside diet and exercise, but does not identify the studies, patient numbers or doses supporting that estimate.
That missing detail matters when translating a headline percentage into a realistic expectation. For someone initially weighing 100kg, a reduction of 10–15 per cent would mean losing 10–15kg. This is an illustration of the reported range, not a prediction for an individual patient.
The publication also describes what it calls real-world data from 2026 involving people who moved from injectable GLP-1 medicines to an oral semaglutide treatment. It reports an average further weight reduction of about 4 per cent over three months.
However, it does not name the dataset, explain how many people were followed or state whether there was a comparison group. Nor does it make clear which injection treatments or doses patients had previously used. The figure therefore cannot establish that switching to a pill produces better results than continuing injections.
A separate claim that some early responders taking the pill exceeded 20 per cent total weight loss after a year is similarly difficult to interpret. Results among selected responders do not show what the average person starting treatment should expect.
How Ozempic and Wegovy differ
Ozempic is a weekly injection containing semaglutide, a medicine that acts on the GLP-1 receptor. It mimics a gut hormone involved in appetite and blood glucose regulation and slows stomach emptying, helping people feel fuller and eat less.
Ozempic is licensed for type 2 diabetes. Wegovy contains the same active ingredient but is licensed for weight management, with different dosing. Sharing an ingredient does not make results from different products, doses or patient groups interchangeable.
Daily Jang refers to stronger results with higher-dose semaglutide and a recently approved oral formulation. It does not specify the country or regulator responsible for that approval, so its account should not be read as confirmation that a particular weight-loss pill is available in the UK.
The report also links greater weight reductions with lower risks of sleep apnoea, kidney problems and heart disease, and describes potential liver benefits in metabolic conditions. It gives no absolute risk figures or study details for these claims. A reader cannot calculate from this account how many patients might avoid a particular illness or cardiovascular event.
These questions form part of the wider examination of GLP-1 medicines beyond weight loss, where each proposed benefit needs to be assessed against the evidence for the specific drug and patient population.
What Daily Jang says about Ozempic side effects
Daily Jang identifies nausea, diarrhoea, constipation and vomiting as the most frequent adverse effects. It says these are particularly noticeable when treatment begins or the dose rises, often easing with time but leading some patients to stop.
The report provides neither the proportion affected nor a typical duration. It therefore cannot tell someone how likely a symptom is at their prescribed dose, or how long it will last.
It also flags muscle loss during rapid weight reduction and describes gallbladder problems as rare, without supplying a numerical frequency. The distinction between losing weight and changing body composition is examined further in our coverage of GLP-1 treatment and muscle loss.
The publication attributes its advice about sustained treatment and lifestyle changes to unnamed experts. It includes no named clinician’s assessment or patient account against which to evaluate that advice.
What remains unresolved about semaglutide treatment
Long-term questions about bone health and excessive weight loss among people who respond strongly remain under investigation, according to the report. It gives no timetable for further findings.
For the newer oral-treatment claims, the next useful evidence would be an identifiable study with participant numbers, doses, starting weights, follow-up periods and treatment discontinuations. Those details would help distinguish a promising observation from a result that can guide prescribing.
For patients considering treatment now, the report advises consulting a doctor before starting because outcomes and risks vary. Its figures offer a broad account of possible benefits and harms, rather than a basis for choosing a formulation, changing a dose or switching from an injection to a tablet.
